BRAIDWELL LP
Long book
$2.63B
Q1 2026
Positions
82
Top-10 weight
32%
concentration
Last quarter
+27.3%
SPY +14.8%
Turnover
44%
of book per quarter
Strategy in plain words
auto-generated from filingsBRAIDWELL LP is a diversified fundamental manager, specialised in healthcare (90% of the long book), running a $2.63B US long book across 82 positions.
The portfolio is moderately concentrated (top 10 ≈ 32% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: CARIS LIFE SCIENCES INC, NEUROCRINE BIOSCIENCES INC, GLAUKOS CORP, CENTESSA PHARMACEUTICALS-ADR, XENON PHARMACEUTICALS INC.
Over the last 9 quarters its long book ran on average 0.5pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-7.8%
Q2 2024
+9.8%
Q3 2024
-8.1%
Q4 2024
-15.1%
Q1 2025
+5.3%
Q2 2025
+14.0%
Q3 2025
+19.6%
Q4 2025
-0.6%
Q1 2026
+27.3%
Sector allocation
Healthcare 89%
Technology 3%
Other 3%
Materials 2%
Services media 2%
Financials 2%
Long book by quarter
What does BRAIDWELL LP own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| CAI CARIS LIFE SCIENCES INC | Healthcare | 8.0M | $143.2M | 5.5% | +2.5% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 652.1K | $85.9M | 3.3% | -13.2% |
| GKOS GLAUKOS CORP | Healthcare | 763.5K | $82.2M | 3.1% | -17.2% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 1.3M | $77.8M | 3.0% | -26.7% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 899.4K | $75.5M | 2.9% | -29.4% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 2.3M | $73.9M | 2.8% | -54.9% |
| IRTC IRHYTHM HOLDINGS INC | Healthcare | 610.2K | $72.0M | 2.7% | +180.7% |
| NUVL NUVALENT INC-A | Healthcare | 700.4K | $71.8M | 2.7% | -14.7% |
| KOD KODIAK SCIENCES INC | Healthcare | 1.8M | $69.3M | 2.6% | -12.3% |
| CGON CG ONCOLOGY INC | Healthcare | 984.8K | $66.7M | 2.5% | -47.4% |
| HNGE HINGE HEALTH INC-A | Technology | 1.5M | $56.1M | 2.1% | +11.5% |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 2.5M | $55.0M | 2.1% | +21.6% |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 3.2M | $52.7M | 2.0% | +238.1% |
| KRYS KRYSTAL BIOTECH INC | Healthcare | 182.4K | $47.1M | 1.8% | -9.7% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 932.8K | $47.1M | 1.8% | -42.9% |
| GH GUARDANT HEALTH INC | Healthcare | 499.7K | $46.2M | 1.8% | New |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 92.9K | $45.7M | 1.7% | +15.1% |
| GENB GENERATE BIOMEDICINES INC | Healthcare | 3.6M | $44.9M | 1.7% | New |
| MBX MBX BIOSCIENCES INC | Healthcare | 1.5M | $44.6M | 1.7% | +46.5% |
| BTSG BRIGHTSPRING HEALTH SERVICES | Healthcare | 1.0M | $43.3M | 1.6% | -15.0% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 1.4M | $43.0M | 1.6% | -27.0% |
| NEO NEOGENOMICS INC | Services media | 5.6M | $41.7M | 1.6% | +21.3% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 478.7K | $40.3M | 1.5% | -16.8% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 539.7K | $39.4M | 1.5% | +66.4% |
| CDNA CAREDX INC | Healthcare | 2.2M | $37.7M | 1.4% | +37.1% |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 77.3K | $35.6M | 1.4% | -7.3% |
| INSP INSPIRE MEDICAL SYSTEMS INC | Healthcare | 677.6K | $34.9M | 1.3% | +25.3% |
| PEN PENUMBRA INC | Healthcare | 105.4K | $34.6M | 1.3% | -4.4% |
| TMDX TRANSMEDICS GROUP INC | Healthcare | 329.4K | $32.7M | 1.2% | +4.5% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 959.3K | $32.1M | 1.2% | -19.2% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 1.7M | $30.5M | 1.2% | +13.8% |
| MRVI MARAVAI LIFESCIENCES HLDGS-A | Healthcare | 10.2M | $29.0M | 1.1% | +22.6% |
| ILMN ILLUMINA INC | Healthcare | 229.2K | $28.3M | 1.1% | -15.0% |
| KYMR KYMERA THERAPEUTICS INC | Healthcare | 337.6K | $28.1M | 1.1% | -25.7% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 497.0K | $28.1M | 1.1% | -17.4% |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 1.8M | $27.1M | 1.0% | -19.8% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 310.6K | $27.0M | 1.0% | New |
| DHR DANAHER CORP | Technology | 139.3K | $26.4M | 1.0% | +17.8% |
| ESTA ESTABLISHMENT LABS HOLDINGS | Healthcare | 463.6K | $26.3M | 1.0% | New |
| TECX TECTONIC THERAPEUTIC INC | Healthcare | 847.2K | $26.2M | 1.0% | -8.7% |
| NTRA NATERA INC | Healthcare | 129.0K | $25.8M | 1.0% | +15.7% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 1.8M | $25.6M | 1.0% | New |
| FULC FULCRUM THERAPEUTICS INC | Healthcare | 3.1M | $24.0M | 0.9% | +2.4% |
| ZURA ZURA BIO LTD | Healthcare | 4.0M | $23.7M | 0.9% | +25.4% |
| ATEC ALPHATEC HOLDINGS INC | Healthcare | 2.2M | $23.6M | 0.9% | New |
| DMRA DAMORA THERAPEUTICS INC | Healthcare | 894.8K | $23.2M | 0.9% | New |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 346.5K | $21.7M | 0.8% | New |
| VERA VERA THERAPEUTICS INC | Healthcare | 523.8K | $21.1M | 0.8% | -33.2% |
| BIOA BIOAGE LABS INC | Healthcare | 1.2M | $21.0M | 0.8% | New |
| CVS CVS HEALTH CORP | Healthcare | 290.7K | $20.9M | 0.8% | -48.5% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 88 | $3.00B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 73 | $3.13B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 73 | $3.37B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 55 | $2.92B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 64 | $2.84B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 73 | $3.86B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 81 | $3.53B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 75 | $3.19B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 70 | $3.10B | canonical | SEC ↗ |